Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.

Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, Sperinde J, Huang W, Allegra CJ, Srinivasan A, Wang Y, Pogue-Geile KL, Lucas PC, Jacobs SA.

J Clin Oncol. 2019 Oct 10;37(29):2601-2609. doi: 10.1200/JCO.19.00858. Epub 2019 Aug 23.

2.

Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ.

J Natl Cancer Inst. 2019 May 20. pii: djz093. doi: 10.1093/jnci/djz093. [Epub ahead of print]

PMID:
31322663
3.

Can we find the positive in negative clinical trials?

Allegra CJ, Goodwin PJ, Ganz PA.

J Natl Cancer Inst. 2019 May 11. pii: djz082. doi: 10.1093/jnci/djz082. [Epub ahead of print] No abstract available.

PMID:
31077298
4.

Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome.

Antignani PL, Allegra C, Fareed J.

Int Angiol. 2019 Feb;38(1):17-21. doi: 10.23736/S0392-9590.18.04031-2. Epub 2018 Nov 20.

5.

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.

Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL.

PLoS One. 2018 Aug 17;13(8):e0200836. doi: 10.1371/journal.pone.0200836. eCollection 2018.

6.

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.

Kolarich A, George TJ Jr, Hughes SJ, Delitto D, Allegra CJ, Hall WA, Chang GJ, Tan SA, Shaw CM, Iqbal A.

Cancer. 2018 Sep 1;124(17):3510-3519. doi: 10.1002/cncr.31527. Epub 2018 Jul 9.

7.

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11. Review.

PMID:
29923599
8.

Pain processing in functional and idiopathic dystonia: An exploratory study.

Morgante F, Matinella A, Andrenelli E, Ricciardi L, Allegra C, Terranova C, Girlanda P, Tinazzi M.

Mov Disord. 2018 Aug;33(8):1340-1348. doi: 10.1002/mds.27402. Epub 2018 May 8.

PMID:
29737565
9.

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).

Kim SR, Song N, Yothers G, Gavin PG, Allegra CJ, Paik S, Pogue-Geile KL.

Br J Cancer. 2018 Mar 6;118(5):629-633. doi: 10.1038/bjc.2017.448. Epub 2017 Dec 14.

10.

Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.

Delitto D, George TJ Jr, Loftus TJ, Qiu P, Chang GJ, Allegra CJ, Hall WA, Hughes SJ, Tan SA, Shaw CM, Iqbal A.

J Natl Cancer Inst. 2018 May 1;110(5):460-466. doi: 10.1093/jnci/djx228.

11.

Treating Congenital Mirror Movements with Botulinum Toxin.

Allegra C, Girlanda P, Morgante F.

Mov Disord Clin Pract. 2017 Sep 25;4(6):895-897. doi: 10.1002/mdc3.12543. eCollection 2017 Nov-Dec. No abstract available.

12.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA.

J Oncol Pract. 2017 May;13(5):333-337. doi: 10.1200/JOP.2017.022152. Epub 2017 Mar 28. No abstract available.

PMID:
28350513
13.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA.

J Mol Diagn. 2017 Mar;19(2):187-225. doi: 10.1016/j.jmoldx.2016.11.001. Epub 2017 Feb 6. Review.

14.

Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA.

Am J Clin Pathol. 2017 Feb 3. doi: 10.1093/ajcp/aqw209. [Epub ahead of print] No abstract available.

PMID:
28165529
15.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA.

J Clin Oncol. 2017 May 1;35(13):1453-1486. doi: 10.1200/JCO.2016.71.9807. Epub 2017 Feb 6. Review.

PMID:
28165299
16.

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Bryan Rumble R, Temple-Smolkin R, B Ventura C, Nowak JA.

Arch Pathol Lab Med. 2017 May;141(5):625-657. doi: 10.5858/arpa.2016-0554-CP. Epub 2017 Feb 6.

PMID:
28165284
17.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.

Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.

JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.

18.

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, Lipchik C, Allegra CJ, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S.

JAMA Oncol. 2016 Sep 1;2(9):1162-9. doi: 10.1001/jamaoncol.2016.2314.

19.

Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.

Chan E, Duckworth LV, Alkhasawneh A, Toro TZ, Lu X, Ben-David K, Hughes SJ, Rossidis G, Zlotecki R, Lightsey J, Daily KC, Dang L, Allegra CJ, King B, George TJ Jr.

J Gastrointest Oncol. 2016 Apr;7(2):173-80. doi: 10.3978/j.issn.2078-6891.2015.071.

20.

Venous hemodynamic changes in lower limb venous disease: the UIP consensus according to scientific evidence.

Lee BB, Nicolaides AN, Myers K, Meissner M, Kalodiki E, Allegra C, Antignani PL, Bækgaard N, Beach K, Belcaro G, Black S, Blomgren L, Bouskela E, Cappelli M, Caprini J, Carpentier P, Cavezzi A, Chastanet S, Christenson JT, Christopoulos D, Clarke H, Davies A, Demaeseneer M, Eklöf B, Ermini S, Fernández F, Franceschi C, Gasparis A, Geroulakos G, Gianesini S, Giannoukas A, Gloviczki P, Huang Y, Ibegbuna V, Kakkos SK, Kistner R, Kölbel T, Kurstjens RL, Labropoulos N, Laredo J, Lattimer CR, Lugli M, Lurie F, Maleti O, Markovic J, Mendoza E, Monedero JL, Moneta G, Moore H, Morrison N, Mosti G, Nelzén O, Obermayer A, Ogawa T, Parsi K, Partsch H, Passariello F, Perrin ML, Pittaluga P, Raju S, Ricci S, Rosales A, Scuderi A, Slagsvold CE, Thurin A, Urbanek T, M VAN Rij A, Vasquez M, Wittens CH, Zamboni P, Zimmet S, Ezpeleta SZ.

Int Angiol. 2016 Jun;35(3):236-352. Epub 2016 Mar 24.

PMID:
27013029
21.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Mar 10;34(8):843-53. doi: 10.1200/JCO.2015.63.0558. Epub 2016 Jan 25.

22.
23.

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.

Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL.

J Clin Oncol. 2016 Jan 10;34(2):179-85. doi: 10.1200/JCO.2015.63.9674. Epub 2015 Oct 5. Review.

PMID:
26438111
24.

The Master Protocol Concept.

Redman MW, Allegra CJ.

Semin Oncol. 2015 Oct;42(5):724-30. doi: 10.1053/j.seminoncol.2015.07.009. Epub 2015 Jul 10. Review.

25.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N.

J Natl Cancer Inst. 2015 Sep 14;107(11). pii: djv248. doi: 10.1093/jnci/djv248. Print 2015 Nov. Erratum in: J Natl Cancer Inst. 2016 Apr;108(4). pii: djw057. doi: 10.1093/jnci/djw057. Erratum in: J Natl Cancer Inst. 2018 Jul 1;110(7):794.

26.

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

George TJ Jr, Allegra CJ, Yothers G.

Curr Colorectal Cancer Rep. 2015;11(5):275-280. Review.

27.

JNCI is 75 years old!

Allegra CJ, Botos J.

J Natl Cancer Inst. 2015 Jan 6;107(1):406. doi: 10.1093/jnci/dju406. Print 2015 Jan. No abstract available.

PMID:
25564599
28.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju333. doi: 10.1093/jnci/dju333. Print 2014 Dec.

29.
30.

Selective high ligation of the sapheno-femoral junction decreases the neovascularization and the recurrent varicose veins in the operated groin.

Mariani F, Mancini S, Bucalossi M, Allegra C.

Int Angiol. 2015 Jun;34(3):250-6. Epub 2014 Jul 16.

PMID:
25027600
31.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N.

J Clin Oncol. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753. Epub 2014 May 5.

32.
33.

Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.

Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.

Int J Cancer. 2014 Jul 1;135(1):128-37. doi: 10.1002/ijc.28675. Epub 2014 Jan 6.

34.

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ.

Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.

35.

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.

Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E.

Br J Cancer. 2013 Oct 1;109(7):1735-43. doi: 10.1038/bjc.2013.523. Epub 2013 Sep 17.

36.

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, Blackmon N, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Jul 3;105(13):989-92. doi: 10.1093/jnci/djt140.

37.

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, Wolmark N.

J Clin Oncol. 2013 Jan 20;31(3):359-64. doi: 10.1200/JCO.2012.44.4711. Epub 2012 Dec 10.

38.

The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report.

Alkhasawneh A, Dong HJ, Liu C, Allegra C, Allan RW.

Case Rep Pathol. 2012;2012:425967. doi: 10.1155/2012/425967. Epub 2012 Oct 17. Erratum in: Case Rep Pathol. 2013;2013:376018. Alkhasawneh, Ahmed N [corrected to Alkhasawneh, Ahmad].

39.

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.

Grothey A, Allegra C.

Ther Adv Med Oncol. 2012 Nov;4(6):301-19. doi: 10.1177/1758834012454464.

40.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.

J Clin Oncol. 2012 Oct 1;30(28):3499-506. Epub 2012 Sep 4.

PMID:
22949147
41.

The Journal of the National Cancer Institute: the next generation.

Allegra CJ.

J Natl Cancer Inst. 2012 Jul 3;104(13):961-2. doi: 10.1093/jnci/djs276. Epub 2012 Jun 30. No abstract available.

PMID:
22751900
42.

Superficial vein thrombosis: a consensus statement.

Kalodiki E, Stvrtinova V, Allegra C, Andreozzi G, Antignani PL, Avram R, Brkljacic B, Cadariou F, Dzsinich C, Fareed J, Gaspar L, Geroulakos G, Jawien A, Kozak M, Lattimer CR, Minar E, Partsch H, Passariello F, Patel M, Pécsvárady Z, Poredos P, Roztocil K, Scuderi A, Sparovec M, Szostek M, Skorski M.

Int Angiol. 2012 Jun;31(3):203-16. No abstract available.

PMID:
22634973
43.

Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.

Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ.

J Clin Oncol. 2012 Feb 1;30(4):406-12. doi: 10.1200/JCO.2011.39.2563. Epub 2011 Dec 27.

44.

Combination therapy for renal cell cancer: what are possible options?

Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH.

Oncology. 2011;81(3-4):220-9. doi: 10.1159/000333470. Epub 2011 Nov 12. Review.

45.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A.

J Clin Oncol. 2011 Nov 1;29(31):4199-204. doi: 10.1200/JCO.2011.35.5867. Epub 2011 Oct 3.

PMID:
21969501
46.

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Wenger JB, Santos N, Liu Y, Dallas J, Subbiah S, Hochwald S, Huang EH, Dang DT, Allegra CJ, Luesch H, Dang LH.

Oncol Rev. 2011 Sep;5(3):177-184.

47.

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N.

J Clin Oncol. 2011 Oct 1;29(28):3768-74. doi: 10.1200/JCO.2011.36.4539. Epub 2011 Aug 22.

48.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

49.

Phlebology training curriculum. A consensus document of the International Union of Phlebology (UIP)-2010.

Parsi K, Zimmet S, Allegra C, Bergan J, Gasparis AP, Labropoulos N, Lee BB, Malouf GM, Partsch H, Rabe E, Ramelet AA, Schadeck M, Vin F; International Union of Phlebology.

Int Angiol. 2010 Dec;29(6):533-59. No abstract available.

PMID:
21173735
50.

Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.

Allegra C, George T Jr, Yothers G.

J Natl Cancer Inst. 2011 Jan 5;103(1):4-5. doi: 10.1093/jnci/djq483. Epub 2010 Dec 1. No abstract available.

PMID:
21123834

Supplemental Content

Loading ...
Support Center